O'Neill Institute  |  June 22, 2018

THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) HAVE SET A GOAL TO ELIMINATE HEPATITIS C AS A PUBLIC HEALTH THREAT BY 2030.

Elimination of Hepatitis C in the U.S. would result in the significant reduction of the incidence of the infection – to the point where cases of the infection are rare and sporadic – as a result of deliberate efforts, with ongoing efforts to maintain the zero prevalence.

In 2017, HHS released its 2017-2020 Viral Hepatitis Action Plan to set the course for elimination of Hepatitis B and C in the U.S.

KEY GOALS OF THE PLAN TO WORK TOWARD ELIMINATION ARE BY 2020 TO:

  • Decrease the number of new HCV infections by at least 60%
  • Increase the number of persons aware of their HCV infection to 66%
  • Reduce the number of HCV-related deaths by 25%
  • Reduce the number of new HCV infections in persons ages 20-39 by at least 60%

In 2016 and 2017. The National Academies of Sciences released a 2-part report on the Feasibility of Eliminating Hepatitis B and C in the U.S. Read part one here and part two here.

THE AVAILABILITY OF CURATIVE HCV DRUG TREATMENTS COULD MAKE HEPATITIS C ELIMINATION A REALITY, BUT ONLY IF THOSE INFECTED KNOW THEIR STATUS, GET TREATMENT, AND COMPLETE THE COURSE OF THERAPY.

KEY POINTS

ELIMINATION OF HEPATITIS C IS FEASIBLE, BUT CRITICAL BARRIERS MUST FIRST BE ADDRESSED:

  1. Poor Surveillance for HCV
  2. Too few people know their status/inadequate screening
  3. High Cost of HCV treatment drugs
  4. Stigma associated with HCV infection
  5. Public opinion that does not deem HCV as a public health priority, due to misinformation and lack of awareness of the illness
  6. Read the National Viral Hepatitis Action Plan here.

Issues

Hepatitis

Latest publications See All

Report

October 14, 2025

Charles Holmes Maggie Little, Ph.D.; Heidi Weimer, J.D., MPH, LL.M; Dylan Green, MPH; Alicia Patterson, Ph.D.; Jonathan Healey; Sydney Luken; Janet Tatenda Bhila; Aleny Couto, MD; Shona Dalal, PhD; Will Fleisher, PhD; Jen Gennai; Rayid Ghani; Peter Godfrey-Faussett; Melissa Goldstein, JD; Kathy Hageman, PhD, MPH; Nina Hasen, PhD; Micheal Ighodaro; Thoko Kalua, MBBS, MSc; Jennifer Miller, PhD; Yogan Pillay, PhD; Anton Pozniak, MD; Miriam Rabkin, MD, MPH; David Ribes, PhD; Lisa Singh, PhD